Araris.png
Araris Biotech AG to Present Data on Antibody-Drug Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024
March 06, 2024 08:00 ET | Araris Biotech AG
AU ZH, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced...
Araris.png
Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical to Develop Next-Generation ADCs Using Araris’ Proprietary Linker-Conjugation Technology
November 08, 2023 02:00 ET | Araris Biotech AG
AU ZH, Switzerland, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris”), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), today announced they...
Araris.png
Araris Biotech AG Initiates Leadership Transition to Advance Next Evolution of Growth in its Antibody-Drug Conjugate (ADC)-Pipeline
October 04, 2023 08:00 ET | Araris Biotech AG
ZURICH, SWITZERLAND, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris”), a company developing ADCs using its proprietary linker-payload technology, today announced the appointment of...
Araris.png
Araris Biotech AG Supported with CHF 2.5M Swiss Accelerator Grant from Innosuisse to Develop Antibody-Drug Conjugate Candidates
May 05, 2023 02:00 ET | Araris Biotech AG
Innosuisse supports 53 companies out of 752 applications with total CHF 112MAraris’ awarded grant will be used to support further development and advancement of Araris’ antibody-drug conjugate (ADC)...
Araris.png
Araris Biotech AG Acquires ARS Pharmaceutical’s Nectin-4 Antibody
April 17, 2023 10:00 ET | Araris Biotech AG
AU ZH, Switzerland, April 17, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the execution of an...
Araris.png
Araris Biotech AG Presents Preclinical Data Highlighting Stable and Efficacious Low Drug-Load ADCs at American Association for Cancer Research (AACR) Annual Meeting 2023
April 14, 2023 12:00 ET | Araris Biotech AG
AU ZH, Switzerland, April 14, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company will deliver...
Araris.png
Araris Biotech AG Announces Strategic Investment with Samsung Ventures
April 11, 2023 22:00 ET | Araris Biotech AG
Samsung Ventures makes investment in ArarisProceeds will be used to support further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates AU ZH, Switzerland, April 11, 2023...
Araris.png
Araris Biotech AG to Present Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023 16:40 ET | Araris Biotech AG
ZURICH, Switzerland, March 14, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced it will be presenting...
Araris.png
Araris Biotech AG to Present at the 22nd Annual PepTalk: Protein Science and Production Week
January 19, 2023 08:00 ET | Araris Biotech AG
ZURICH, Switzerland, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Bernd Schlereth,...
Araris.png
Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer
October 12, 2022 10:15 ET | Araris Biotech AG
AU ZH, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of...